Ruconest conestat alfa regulatory update

Pharming said partner MegaPharm Ltd. (Raanana, Israel) received marketing approval and full reimbursement in Israel for Ruconest conestat alfa to treat acute angioedema attacks in adults with hereditary angioedema (HAE). MegaPharm plans to launch the recombinant human complement 1 (C1) esterase inhibitor in the country this quarter. MegaPharm has Israeli commercialization rights to the product from Pharming under a 2011 deal (see BioCentury, June 13, 2011). ...